Introduction 1
Patients presenting for surgery due to conditions associated with chronic pain 2 frequently are being treated with opioids, often at alarmingly high doses. One study of 3 Medicaid enrollees found that 63.5% of patients with non-cancer chronic pain had taken 4 an opioid in the prior 12 months, an increase of 18.9% from five years prior. 1 Yet despite 5 escalating doses of opioids, patients continue to report that their chronic pain is not well 6 controlled. 2 At the same time, serious adverse drug effects (ADEs) associated with 7 opioids, including fatal respiratory depression, continue to be a serious concern. 3 In 8 patients chronically taking opioids, tolerance to respiratory depression is incomplete 4 and 9 such patients have an increased risk of overdose and death compared to non-opioid 10 users. 5 Analgesic alternatives to opioids are, therefore, highly desirable. 11
One such alternative during the perioperative period is ketamine, an 12 N-methyl-D-aspartate (NMDA) receptor antagonist. A role of the NMDA receptor in the 13 development of opioid tolerance was suggested by studies from several decades ago. 6, 7 
14
Ketamine is a potent analgesic that does not cause respiratory depression, and may 15 improve postoperative analgesia while reducing opioid consumption. 8, 9 As an additional 16 potential benefit, recent evidence suggests that intravenous (IV) ketamine may decrease 17 the incidence of persistent postsurgical pain (PPSP). 10 Ketamine infusions at our 18 institution have been used both intraoperatively by the anesthesia team and 19 postoperatively by the acute pain management service (APMS) as part of an 20 opioid-sparing strategy in complex, opioid-tolerant patients. 21
We had three primary objectives of the current study: 1) to identify factors 22 associated with current decisions by anesthesiologists to initiate ketamine during spine 23 surgery; 2) to identify specific spine procedures in which ketamine has been used most 1 frequently; and 3) to identify ADEs associated with all postoperative ketamine infusions 2 and which ADEs most frequently led to discontinuation. This information is necessary 3 for us to design prospective, randomized clinical trials comparing IV ketamine to placebo 4 in opioid-tolerant patients. Spine surgery was chosen to study in detail because it is 5 typically associated with moderate to severe postoperative pain, over 50% of our 6 ketamine use has been in spine surgery, and this is a high-volume service at our 7 institution. We retrospectively analyzed the preoperative medications and surgical details 8 of all patients over a three-year period who underwent any type of elective spine surgery 9
and also examined a sample of postoperative patients from all surgical specialties who 10 received ketamine infusions for the presence of ADEs and classified them. 11 
Demographics and Preoperative Medications Associated with Ketamine Administration 2
There were 4958 patients who underwent elective spine surgery under general 3 anesthesia during the study interval, 4748 of which were entered into our electronic 4 preoperative anesthesia system and had data available for analysis, and 211 of whom 5 received an intraoperative infusion of ketamine. Among all patients, those receiving 6 ketamine were younger (difference = -4.4 years, 95% CI -2.2 to -6.0 years, P <10 -6 ), had 7 a higher ASA Physical Status (P <10 -6 ), and were scheduled for surgeries of longer 8 estimated duration (difference = 72 minutes, 95% CI 60 to 84 minutes, P <10 -6 ), ( Table  9 1). There were no significant differences in weight or BMI between the two groups. 10
Males and females were represented equally (difference = -0.40%, 95% CI -3.1% to 11 2.3%, P = 0.77). 12
Medication factors at the time of the preoperative evaluation associated with a 13 greater likelihood of receiving an intraoperative ketamine infusion were taking vs. not 14 taking a scheduled opioid (OR 16.09, 95% CI 11.98 to 21.59), taking any opioid vs. no 15 opioid (OR 10.25, 95% CI 7.13 to 14.75), and taking vs. not taking an anti-depressant 16 (OR 2.69, 95% CI 2.02 to 3.57) ( Table 2) . Patients who were taking both a scheduled 17 opioid and an anti-depressant were more likely to receive ketamine than those taking just 18 a scheduled opioid (OR 1.64, 95% CI 1.11 to 2.46; Table 2 ). 19
Among the 552 patients who were taking a scheduled opioid at the time of the 20 preoperative evaluation, those receiving a ketamine infusion were younger (difference 21 = -2.8 years, 95% CI -0.6 to -5.1 years, P = 0.012), had a higher ASA Physical Status (P 22 = 0.01), and were scheduled for surgeries of longer estimated duration (difference = 49 23 minutes, 95% CI 32 to 67 minutes, P <10 -6 ), (Table 3) . There were no significant 1 differences in weight or BMI between the two groups. There was a higher proportion of 2 females (difference = 13.3%, 95% CI 4.3 to 22.3%, P = 0.005). 3 4
Surgical Procedures Associated with Ketamine Administration 5
There were 20 distinct spine procedures (12 primary spine procedures and 8 6 revision spine procedures) identified in the database (Table 4 ). Of these, there were 10 7 procedures that had  5% prevalence of intraoperative ketamine administration. The three 8 most commonly performed of these 10 were posterior thoracic/lumbar fusion (N = 148 9 cases), anterior thoracic/lumbar fusion (N = 136 cases), and anterior/posterior cervical 10 fusion (N = 137 cases). Specific spine procedures are displayed in Table 4 according to  11 primary or revision status. 12 
13

Side Effects of Low-Dose Ketamine Infusions 14
There were 31.8% of patients who experienced at least one ADE (Table 5 ). The 15 most frequent ADE was CNS excitation (16.2%), followed by sedation (9.4%) and visual 16 disturbances (3.1%). Some patients experienced more than one ADE (Table 5 ). Thirty-17 seven patients (36.3% of all patients with an ADE) experienced ADEs severe enough to 18 have resulted in discontinuation of the ketamine infusion. The reasons for infusion 19 discontinuation are described in Table 5 . Sedation was the ADE most likely to result in 20 ketamine discontinuation. Of the 37 patients whose infusions were discontinued, 35 of 21 them reported resolution of symptoms after the infusion was stopped. Twenty-six patients 22 received benzodiazepines, commonly used for treatment of side effects at our hospital, 23 In this observational study, we found that patients who received intraoperative 2 ketamine infusions tended to be younger, sicker, and undergoing spine procedures of 3 longer duration (i.e., more complex) than those who did not. Patients who received 4 ketamine infusions were more likely to be taking preoperative opioids, and this increased 5 if patients were taking opioids on a scheduled basis. 6 We found that patients who were most likely to receive ketamine were those 7 undergoing the most complex spine procedures, often involving both an anterior and 8 posterior component or a revision procedure (Table 4) . Previous studies examining 9 ketamine in spine surgery have yielded conflicting results regarding postoperative opioid 10 consumption. 8, [11] [12] [13] The lack of consistent findings may have resulted, in part, from 11 combining potentially different procedures, listed as "lumbar fusion,"
8 "lumbar or 12 thoracolumbar laminectomy and fusion," 12 or "elective spine surgery." 13 Our data, 13 however, suggest that anesthesiologists viewed patients undergoing longer, complex 14 procedures differently than less complex cases. For example, one of the most common 15 procedures, primary posterior lumbar fusion, had a low prevalence of ketamine 16 administration, suggesting that providers believed conventional opioid analgesia was 17 adequate. Patients who may benefit most from ketamine should be targeted for future 18 studies examining important long-term outcomes of interest. Those patients undergoing 19 presumably less painful procedures with lower incidence of persistent postsurgical pain, 20 such as primary posterior lumbar fusion or anterior cervical fusion, may be able to be 21 managed with conventional therapy. Consistent with previous studies, 9 the more complex 22 and painful spine procedures were the ones most likely to be associated with ketamine 1 administration as a continuous infusion. 2
The apparent increased prevalence of ketamine use in patients taking both anti-3 depressants and scheduled opioids was not surprising as the link between chronic pain, 4
anti-depressants, opioids, and spine surgery has been described. 14 Although it is 5 impossible to determine retrospectively if this combined therapy factored into the 6 decision-making process by the anesthesia team, anti-depressant use is a potential 7 confounder that should be controlled for in future studies comparing ketamine to other 8 therapies. 9
Our results also confirm the tolerability of ketamine's ADEs in a clinical setting 10 (Table 5 ). This agrees with clinical trials in which up to 0.25 mg/kg/hr have been tried 11 without major ADEs. 13 Our observed prevalence of central nervous system ADEs 12 (16.2%) is similar to the 22% retrospectively described by Rasmussen. ADEs resulting from simultaneous administration of opioids and benzodiazepines, as 21 well as variable patient sensitivity to ketamine, some of which may be related to 22 individual changes at the cellular level. 17 There may be other unidentified factors as well. 23
Because 35 out of the 37 patients had resolution of symptoms once the infusions were 1 stopped, this suggests that the side effects were at least partially due to ketamine. 2 Using the data from this observational study, we are currently designing a 3 prospective, randomized trial comparing intra-and postoperative ketamine infusions to 4 placebo in opioid-tolerant patients undergoing complex spine surgery with particular 5 focus on long-term outcomes. Only complex spine procedures that are more likely to 6 result in severe pain will be included (i.e. anterior/posterior procedures or procedures 7 involving two or more spine areas, such as thoracic and lumbar). We will use the 8 frequency of ADEs encountered to guide the process of obtaining informed consent. The 9 ADE data could also be used as a guide for any hospitals considering starting a ketamine 10 service on the general medical floors. 11
Our study may have limited generalizability in that the decision to start an 12 intraoperative ketamine infusion was made at the discretion of the attending 13 anesthesiologist for the case. Thus, our findings may not apply to all practices. Second, 14 some patients may have been inappropriately placed in the "scheduled" opioid group 15 rather than the "as needed" group or vice versa due to documentation issues or patients 16 misrepresenting their opioid use. 17
In conclusion, we confirmed that postoperative ketamine infusions may be given 18 safely on general medical floors without special monitoring or intensive care, and 19 intraoperative infusions tend to be started for patients taking opioids, especially 20 scheduled opioids. Our data provide guidance both for hospitals considering the use of 21 ketamine infusions and for the design of future prospective, randomized clinical trials 22 looking at long-term benefits of ketamine or its ADEs. 23
